58 results about "Embolization Therapy" patented technology

Apparatus (20) for treating a subject (30) suffering from spontaneous atrial fibrillation includes an electrode device (22), adapted to be coupled to a site of the subject (30) selected from the list consisting of: a vagus nerve (24) of the subject (30), an epicardial fat pad of the subject (30), a pulmonary vein of the subject (30), a carotid artery of the subject (30), a carotid sinus of the subject (30), a vena cava vein of the subject (30), and an internal jugular vein of the subject (30), and a control unit (32), adapted to drive the electrode device (22) to apply an electrical current to the site, and to configure the current to maintain the spontaneous AF for at least about 24 hours, so as to modify blood flow within the atria and reduce risk of thromboembolic events.

Embodiments are related to the accurate detection of somatic mutations in the plasma (or other samples containing cell-free DNA) of cancer patients and for subjects being screened for cancer. The detection of these molecular markers would be useful for the screening, detection, monitoring, management, and prognostication of cancer patients. For example, a mutational load can be determined from the identified somatic mutations, and the mutational load can be used to screen for any or various types of cancers, where no prior knowledge about a tumor or possible cancer of the subject may be required. Embodiments can be useful for guiding the use of therapies (e.g. targeted therapy, immunotherapy, genome editing, surgery, chemotherapy, embolization therapy, anti-angiogenesis therapy) for cancers. Embodiments are also directed to identifying de novo mutations in a fetus by analyzing a maternal sample having cell-free DNA from the fetus.

Methods for quantitative perfusion analysis for embolotherapy are presented. The method quantitatively measures blood flow changes based on angiographic information. The method may provide potential evaluation of optimal embolization endpoints in vascular vessels. The method may be used in various applications such as transcatheter arterial chemoembolization (TACE), or other medical procedures that affect blow flow within bodily tissues. The method is applicable towards treatment of tumors in liver, kidney, brain, and other organs.

The invention discloses a magnetic resonance imaging detectable in-situ liquid crystal precursor embolism composition which comprises the following components: an MRI water-soluble or water-insoluble contrast medium, a liquid crystal material, a physiological acceptable water-soluble organic solvent and water. The following components can be added according to the treatment goal and the clinical demand: an X ray-impermeable water-soluble or water-insoluble contrast medium and/or drugs. The MRI detectable liquid embolism composition disclosed by the invention has the characteristics of low viscosity, no toxicity, low cost and fast curing, can be injected, and is mainly used in local embolism treatment and relevant imageological examination of tumors, vascular malformation and hemostasis.

The invention relates to the technical field of medical instruments, and discloses a net basket type thrombus removing device. The device comprises a far-end filtering disc, a near-end recycling discand at least one middle thrombus taking disc; the far-end filtering disc can be elastically expanded in the radial direction, and is provided with a net-shaped structure; the far-end filtering disc, the middle thrombus taking disc and the near-end recycling disc are sequentially and coaxially connected; in a natural unfolding state, the middle thrombus taking disc is in a flat disc shape; and thediameter of the middle thrombus taking disc is larger than that of the far-end filtering disc. According to the embodiment of the invention, a rapid, safe and effective thrombus removing mode can be provided for embolism treatment of pulmonary artery embolism and other large-size and thrombus-amount embolism, so that the treatment effect of acute middle-high risk pulmonary embolism patients can beimproved.

A method for preparing a degradable drug-loaded microsphere for embolization and a product obtained therefrom, includes the steps of: dissolving a degradable material in an organic solvent, then adding a drug and mixing well to form a suspension or solution; then pouring the drug-containing suspension or solution into an aqueous solution of polyvinyl alcohol, stirring, and thereafter adding water twice for dilution, to prepare the degradable drug-loaded microsphere. The microsphere prepared by the present invention has the advantages of having a controllable particle size, a high drug loading capacity, and a regular spherical shape, being convenient for sieve sizing and accurate particle-size indication, and being accurately targeted to an embolized blood vessel, and the like, and thus has a good application prospect in interventional embolization therapy.

The invention discloses a preparation method and a use of a liquid embolism agent having drug loading and developing functions. The liquid embolism agent is formed through mixing anion-modified polyethylene-polyvinyl alcohol copolymer (EVOH), a solvent and a developer according to a certain ratio. Negative ion groups are introduced to the high molecular chain of the EVOH through a chemical modification or grafting modification technology, and the negative ion groups can adsorb and load cationized chemotherapeutic anticancer drugs through positive and negative charge interactions. The solvent can be dimethyl sulfoxide (DMSO), N-methylpyrrolidone (NMP) or ethanol or a mixture of the DMSO, NMP and ethanol. The developer is a metallic tantalum micro-powder or an iodine-containing contrast agent or a mixture of the metallic tantalum micro-powder and the iodine-containing contrast agent. The liquid embolism agent can be widely applied to interventional embolization therapy, and is especiallysuitable for transcatheter arterial chemoembolization (TACE) therapy of liver cancer.

The invention discloses a drug sustained-release alginic acid embolism microsphere and a one-step electrostatic spraying preparation method thereof. Sodium alginate is compounded with a chemotherapeutic drug with positive charges, and the drug-loaded alginic acid embolic microsphere is prepared through a multi-nozzle one-step electrostatic spraying technology, so that combined treatment of embolism treatment and chemotherapy is realized. According to the multi-nozzle one-step electrostatic spraying preparation method provided by the invention, the drug sustained-release embolism microsphere can be prepared in one step, the prepared microsphere is uniform in particle size and controllable in size, the diameter is 100-1000 microns, and the microsphere has the potential of large-scale production. According to the alginic acid embolism microsphere provided by the invention, the drug loading capacity of common embolism microspheres is greatly improved, long-term slow release of chemotherapeutic drugs can be realized, nutrient source blood supply required by tumor growth can be blocked, the local drug concentration of a focus part can be improved, and meanwhile, the drug concentration inother organs is reduced, toxic and side effects are reduced, synergistic treatment of embolism treatment and chemotherapy is achieved, and the method has great development prospects.

The invention discloses an intracranial dense mesh stent with an anticoagulant coating. The intracranial dense mesh stent comprises a dense mesh stent body and a hydrophilic polymer material covering the dense mesh stent body, wherein the dense mesh stent body is coated with the anticoagulant coating. According to the intracranial dense net stent, not only can a channel be reconstructed for blood vessels, but also antithrombotic treatment can be carried out on the blood vessel wall at the position of stent implantation, and embolism treatment can be carried out on aneurysm at the same time.

The invention belongs to the technical field of medical test instruments and particularly relates to an in-vitro simulation device for vascular intervention embolism treatment. The device comprises apulse pump, an organ artery module, a basic blood vessel module and a supporting structure, wherein the pulsation pump is used for supplying blood to the simulated heart pulsation; the organ artery module comprises a renal artery module, a hepatic artery module and a splenic artery module which are respectively used for simulating renal artery embolism, hepatic artery embolism and splenic artery embolism; the basic blood vessel module is used for simulating a basic blood vessel passage for the interventional catheter to enter the body; and the supporting structure is used for supporting and fixing the modules and maintaining the shape of blood vessels. The device is high in blood vessel reduction degree, can be modified according to the specific illness state, is transparent and visual, and can accurately simulate the embolism part and the embolism process.

The invention provides a multifunctional liquid metal embolizing agent as well as a preparation and an application thereof. The multifunctional liquid metal embolizing agent is prepared from liquid metal, functional nanoparticles and a high polymer material, wherein the liquid metal is spherical and forms an inner core of the embolization agent; the functional nanoparticles are dispersed on the surface of the liquid metal; and the high polymer material coates outside the inner core and the functional nanoparticles. The multifunctional liquid metal embolization agent provided by the invention can realize the functions of embolization, CT imaging, MRI imaging, drug loading, thermal conversion, magnetism and the like, and is expected to realize the combination of targeted embolization treatment with chemotherapy, thermal therapy and radiotherapy; and the preparation method of the multifunctional liquid metal microsphere embolization agent provides possibility for more quickly and conveniently preparing the multifunctional microsphere embolization agent with multiple curative effects and diagnosis and treatment integration.

The present invention provides a vascular treatment material which has high safety, and also can exert high organization acceleration effect. The present invention also provides a commercially available vascular treatment material, which is easy to produce and can be easily sterilized, and also can be stored for a long period. Disclosed is a vascular treatment material including a coil on which statin is loaded. It is preferred that a wire forming the coil is made of at least one kind of metal selected from platinum, tungsten, gold, cobalt, chromium, titanium, niobium, aluminum, tantalum, iron, nickel and the like. The vascular treatment material of the present invention is particularly useful, which is placed in a blood vessel for embolization treatment, or which accelerates organization for prevention of recanalization of aneurysm or for prevention of rupture of aneurysm.

The invention discloses a preparation method of high-drug-loading degradable alginate sulfate vascular embolization microspheres. The preparation method comprises the following steps of: S01, preparing an aqueous phase; S02, preparing an oil phase; S03, preparing alginate sulfate microspheres; and S04, preparing drug-loaded alginate sulfate embolization microspheres. The invention also discloses the high-drug-loading degradable alginate sulfate vascular embolization microspheres obtained by the preparation method of the high-drug-loading degradable alginate sulfate vascular embolization microspheres and application of the high-drug-loading degradable alginate sulfate vascular embolization microspheres in preparation of an embolization agent for transcatheter arterial chemoembolization treatment. The alginate sulfate vascular embolization microspheres disclosed by the invention have good biocompatibility and are biodegradable, and the degradation product is safe and non-toxic. The preparation method has the advantages of simplicity and convenience in operation, high repeatability, mild conditions and the like, the prepared microspheres are uniform and controllable in particle size, and the vascular embolization microspheres prepared by the invention have good application prospects in the field of tumor interventional therapy.

The invention relates to a locally enhanced nickel-titanium alloy intracranial stent, and belongs to the field of medical equipment. The intracranial stent can be used for assisting coil embolizationto treat intracranial aneurysms. An intracranial stent main body has a tubular structure formed by using single rhombus units composed of sine wave structures and connecting rods and double rhombus units each formed by combining two single rhombus units. The double rhombus units can improve the flexibility of the stent, and the single rhombus structures can guarantee the stability and supporting performance of the stent to a certain extent; and in addition, by adjusting the position and number of different-shape units, a plurality of stent structures can be designed and changed to achieve different mechanical characteristics. According to the locally enhanced nickel-titanium alloy intracranial stent design based on the mixed unit structure, an optimized unit ratio can be designed in different use environments, supporting enhancement at specific positions (such as a tumor path opening) can be realized on the premise that compliance of the stent is guaranteed, and the stent can be used for assisting the coil embolization.

The present invention relates to a device (2) for automatically quantifying intravascular embolization success, comprising a registration unit (4) adapted for registering a first image and a second image, a segmentation unit (6) adapted for segmenting a tissue of interest in the first image and in the second image and an evaluation unit (8) for evaluating a deviation of perfusion of the tissue of interest by comparing the first image and the second image. The first image is obtained before an interventional treatment, whereas the second image is obtained after such a treatment. Evaluating may comprise comparing the segments of the first and the second images and thus providing a quantitative measure for a perfusion deviation of the tissue, e.g. the perfusion deviation of a tumorous tissue before and after an embolization treatment.

Provided are the use of poly(N-isopropylacrylamide-co-butyl methacrylate) in preparing an embolism material for blood vessels, an embolism material for blood vessels and the use thereof in preparation of drugs. The embolism material for blood vessels comprises poly(N-isopropylacrylamide-co-butyl methacrylate) and a dispersion medium consisting of an electrolyte, a contrast agent, a pH regulator and water. The concentrations of the polymer, electrolyte and contrast agent are respectively 5-30 mg/ml, 0.1-30 mg/ml and 100-350 mg/ml based on iodine. The embolism material for blood vessels is suitable for embolization therapy of tumors in hypervascular and parenchymal visceral organs.

The invention discloses an absorbable tubular stent. The absorbable tubular stent is characterized in that the tubular stent is made by blending of polylactic acid and acylated chitosan, and the wall of the tubular stent is provided with or without a porous structure or pattern structure. Due to addition of the acylated chitosan, local acidity generated by the polylactic acid in degradation can be regulated, and oligosaccharides and monosaccharide obtained by degradation of the acylated chitosan can be absorbed and used by organisms, so that high biocompatibility, degradability and absorbability are achieved; the tubular stent has excellent mechanical strength and press resilience. The absorbable tubular stent can be planted in vivo by surgeries to serve as an intravascular stent and is applicable to treatment of embolism or blood vessel lumina narrowing caused by vascular diseases; the absorbable tubular stent can also serve as a biliary stent to be applied to treatment of cholestasis and pancreaticobiliary obstruction caused by pancreatobiliary neoplasms; the absorbable tubular stent can further serve as a urethral stent to be applied to treatment of dysuria resulted from urethral compression caused by prostatic hyperplasia. The absorbable tubular stent can be degraded and absorbed in vivo finally along with lesion repair, in-vivo long-term retention is avoided, and the absorbable tubular stent has a promising market prospect.